Clinical Trials Logo

Immune Response clinical trials

View clinical trials related to Immune Response.

Filter by:

NCT ID: NCT02002156 Completed - Immune Response Clinical Trials

A Study of the Interaction Between BCG And MenC Immunisation: BAM

BAM
Start date: June 20, 2014
Phase: Phase 4
Study type: Interventional

The Bacille Calmette-Guérin (BCG) vaccine is the only vaccine licenced to prevent tuberculosis (TB). The stimulus it gives to the immune system allows it to respond more effectively to a subsequent infection with TB. Many studies have shown that BCG is effective in reducing deaths from TB disease, particularly in children. However, there is also evidence that in countries with a relatively high death rate, BCG reduces this death rate but by more than would be expected by its effect on TB alone. This controversial but important finding warrants further and serious consideration. One possibility is that BCG, in addition to stimulating the immune system against TB, also has a positive effect on the way the immune system works more generally. This might mean a more effective response to serious infections that are completely unrelated to TB, or the ability to respond better to other routine childhood vaccines, or to maintain such responses for longer. In these examples, the timing of BCG administration in relation to other vaccines could be crucial. This study will recruit 30 healthy babies who would not routinely be offered the BCG vaccine in the UK within the first week of life. Babies will be assigned at random to one of three groups of ten babies each. BCG will be given to one group of babies around birth, one at three months old and the last group will not get BCG during the study. Babies will stay in the study until 13 months old and have five blood tests over this period. This preliminary study will look at the participants' blood to see if there are differences in the immune system, or its response to the MenC childhood meningitis vaccine or the pattern of genes activated after BCG has been given.

NCT ID: NCT01861613 Completed - Hepatitis B Clinical Trials

Seroprevalence of Hepatitis B and Immune Response to Hepatitis B Vaccination in Chinese College Students

Start date: September 2009
Phase: Phase 4
Study type: Interventional

At present, children less than 15 y of age have been regarded as a key group for hepatitis B immunization in China. However, there is not yet special immunization strategy for population above 15 y of age. In this study, we investigated the seroprevalence of hepatitis B and immune response to HB vaccine among Chinese college students to uncover the need on universal mass vaccination or booster immunization only for students with HBV vaccination history against hepatitis B in Chinese college students to inform decision making.

NCT ID: NCT00902278 Completed - Immune Response Clinical Trials

Immune Responses Induced by Different Licensed Influenza Vaccines

Start date: October 2008
Phase: N/A
Study type: Interventional

The goal of this research is to find out how the body's immune system responds to different manufacturer's "flu" vaccines.

NCT ID: NCT00548990 Completed - Immune Response Clinical Trials

The Immune Function Intervention Trial

ImFIT
Start date: August 2002
Phase: N/A
Study type: Interventional

The purpose of the study is to examine whether cardiovascular exercise training improves immune responses to vaccination in previously sedentary older adults.

NCT ID: NCT00346619 Completed - Immune Response Clinical Trials

Determining the Amount of Time Needed for Nelfinavir to Boost the Immune System in Adults

Start date: October 2005
Phase: Phase 1
Study type: Interventional

Our group has shown that HAART increases the thymic production of naïve T cells in the healthy adult, thereby boosting the immune system. We propose to investigate the amount of and length of Nelfinavir therapy necessary to increase those cells in adults. Subjects will be treated with Nelfinavir, and blood will be sampled at variable times to determine the immune response in peripheral blood.